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To understand how antibiotic use affects the risk of a resistant
infection, we present a computational model of the population
dynamics of gut microbiota including antibiotic resistance-con-
ferring plasmids. We then describe how this model is parameter-
ized based on published microbiota data. Finally, we investigate
how treatment history affects the prevalence of resistance among
opportunistic enterobacterial pathogens. We simulate treatment
histories and identify which properties of prior antibiotic expo-
sure are most influential in determining the prevalence of resis-
tance. We find that resistance prevalence can be predicted by
3 properties, namely the total days of drug exposure, the dura-
tion of the drug-free period after last treatment, and the center
of mass of the treatment pattern. Overall this work provides a
framework for capturing the role of the microbiome in the selec-
tion of antibiotic resistance and highlights the role of treatment
history for the prevalence of resistance.
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Pathogenic bacterial species interact with the microbiome andare often part of the microbiome themselves (1), which
makes the problem of antibiotic resistance more challenging
both in terms of understanding the drivers of resistance and in
terms of management and prevention of resistance. The former
challenge arises because the pathogen–microbiome interactions
imply that a full understanding of the dynamics of resistance
necessitates also a quantitative understanding of the microbial
ecosystem inhabiting an individual host. The latter challenge
results from the effects of collateral selection and cross-species
exchange of resistance that this interaction enables. The grave
resistance crisis in enterobacterial infections (2–6) is a case in
point for these challenges, as arguably the interactions with the
highly diverse microflora and the horizontal genetic transfer of
resistance by conjugative plasmids are a major driver of the high
level of resistance observed in Enterobacteriaceae.
In recent years, metagenomic studies have generated an
unprecedented wealth of data on the composition and dynam-
ics of microbial communities (7–13). However, translating this
knowledge into predictions on the impact of the microbiome
on resistance evolution is difficult. One way to move from a
description of the microbiome to a mechanistic understand-
ing and predicting its effect on antibiotic resistance is math-
ematical models that integrate both the rich data on micro-
biome compositions and the processes of resistance evolution.
Although there are numerous studies on modeling plasmid-
mediated resistance evolution (14–19) and dynamics of the
microbiome (20–26), a composite mathematical model which
includes both does not exist to our knowledge. The distinctive-
ness of our model lies in the integration of these 2 indepen-
dently investigated lines of research, namely the dynamics of
microbial communities and resistance evolution via horizontal
gene transfer.
Antibiotic use is one of the major drivers of antibiotic resis-
tance and this effect is at least partially mediated by the micro-
biome. Therefore, one important application of such models is
to investigate the expected association between antibiotic use
and antibiotic resistance at the level of individual patients. On
the epidemiological level, antibiotic consumption is known to
correlate with prevalence of resistance (27). Similarly, on the
level of the individual treated patient, past antibiotic exposure
is associated with increased risk of treatment failure (28–38).
Specifically for plasmid-conferred resistance, prior antibiotic use
is an independent risk factor for AmpC- and extended spectrum
beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella
pneumoniae infections (39–41). The use of antimicrobial agents
generates a selection pressure that allows resistant enterobac-
teria to become effective intestinal colonizers and potentially
cause infections which are hard to treat. To prescribe more effec-
tive empirical antimicrobial therapy, clinicians need to have an
increased awareness of the factors affecting the prevalence of
resistance among enterobacteria, including which patients are at
risk for infection (42) and what aspects of past antibiotic con-
sumption drive an individual’s risk of carrying and spreading
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resistance. A recent study identified a strong association of
antibiotic resistance with the history of drug purchases of the
patients and showed that the use of information on treatment
history can greatly reduce the risk of mismatched treatment
compared with the current standard of care (43).
To address the effect of treatment history on the prevalence
of resistance for an enterobacterial infection with plasmid-
conferred resistance, we first develop a computational frame-
work that describes the within-patient population dynamics of
the gut microbial community and its plasmids and parameterize
it based on published data. Next, we use the model to simulate
treatment histories, where the initiation, duration, and num-
ber of treatments are randomized. We then identify the most
important characteristics of the random treatment histories in
determining the prevalence of resistance. By doing so, we show
that the impact of prior antibiotic exposure can be captured by
focusing on 3 properties of the treatment history, which are the
total days of drug exposure, the duration of the drug-free period
after last treatment, and the center of mass of the treatment
pattern. Furthermore, we demonstrate that the most relevant
information on the prevalence of resistance is contained in the
most recent treatments of the patient.
Results
Model. Our mathematical model describes the following general
scenario: A patient is colonized with a microbial gut commu-
nity harboring an opportunistic pathogen belonging to phyla
Proteobacteria, which may cause an infection by translocat-
ing to the blood stream, by migrating to other organs, or via
fecal contamination of skin and other body sites (44–47). We
assume that the community also harbors a harmless commensal
Bacteroidetes population, bearing conjugative plasmids confer-
ring resistance to quinolones, forming a reservoir of plasmid-
mediated quinolone resistance (PMQR) genes in the gut micro-
biome. These genes are horizontally transferred between the
harmless and the pathogenic commensals and maintained in the
gut microbiome for a certain amount of time even in the absence
of treatment. We assume that the patient occasionally received
antibiotic treatment(s) in the past, which we refer as the treat-
ment history. Due to the selection pressure imposed during this
treatment period, prevalence of resistance among the gut com-
munity increases, thus increasing the possibility of a resistant
infection to occur. An illustration of the model scenario and
the summary of the dynamical model of the gut microbiome are
given in Fig. 1 A and B, respectively. We use this model to inves-
tigate how past antibiotic treatment affects the prevalence of
resistance—a proxy for the risk of treatment failure—measured
by the frequency of resistance within the opportunistic pathogen
population in the gut. Specifically we focus on treatment with
ciprofloxacin (CIP) and PMQR.
We first develop a system of ordinary differential equations
describing the rate of change of the population size of each
phylum over time (Fig. 1B). We then estimate the interaction
and growth parameters using the operational taxonomic unit
(OTU) reads of gut microbiome provided in ref. 11. Conjuga-
tion frequencies, resistance costs, and missegregation fraction
are jointly assigned to achieve a plausible decay rate for the
plasmid, which is assumed to be 2 y (720 d). Bacterial death
rates are obtained based on the quantitative and qualitative
results published in the literature (see Table 3). Details on
the estimation methods are provided in Materials and Methods.
Statistics on the growth and interaction parameter estimates are
provided in SI Appendix, Table S1 and Fig. S1, and the corre-
sponding time series estimations of the phylum-level abundances
are provided in SI Appendix, Fig. S2. Statistics on death rates,
conjugation frequencies, resistance costs, and missegregation
fraction are given in SI Appendix, Table S2, and the correspond-
ing parameter distributions are provided in SI Appendix, Figs.
S5 and S6. A hybrid stochastic–deterministic simulation method
(48) is adopted to simulate the model to capture the stochastic
extinction of the plasmid-bearing bacteria. Briefly, this method
approximates the fast reactions associated with species with high
abundance as continuous processes, whereas all other reactions
are still realized as discrete stochastic processes, thus decreasing
the computational cost.
Using the parameterized model, we show a 10-d treatment
45 d after initial colonization with the resistant reservoir in Fig. 2
A and B, where the absolute and relative abundances of phyla are
presented, respectively. For the sake of convenience in notation,
we denote the phyla Proteobacteria, Bacteroidetes, Firmicutes, and
Actinobacteria by C0, C1, C2, and C3, respectively. Plasmid-
bearing counterparts of C0 and C1 are denoted by C+0 and C
+
1 ,
respectively. As seen in Fig. 2A, the resistant reservoir C+1 starts
to decline in the absence of treatment, while causing an initial
increase of the C+0 population via conjugation. During the appli-
cation of treatment, both plasmid-bearing populations C+0 and
C+1 increase, whereas all sensitive phyla decrease in abundance.
After the treatment is stopped, sensitive phyla recover back to
their pretreatment population sizes, while the plasmid-bearing
populations start to decline again due to the absence of drug
pressure. The assumptions on relative abundances of phyla dur-
ing and after CIP treatment (49–52) can be observed in Fig. 2B,
where the relative abundances of Proteobacteria and Firmicutes
decrease and the relative abundance of Bacteroidetes increases.
A B
Fig. 1. (A) Illustration of the model scenario. (B) Summary of the dynamical model of the gut microbiome.








































Fig. 2. Demonstration of the model behavior for a 10-d treatment 45 d after initial colonization with the resistant reservoir. C0, C1, C2, and C3 denote the
phyla Proteobacteria, Bacteroidetes, Firmicutes, and Actinobacteria, respectively. (A) Absolute abundances of C0, C1, C2, C3, C
+
0 , and C
+
1 in response to a
10-d CIP treatment. (B) Relative abundances of C0 + C
+
0 , C1 + C
+
1 , C2, and C3 in response to a 10-d CIP treatment.
Simulated Treatment Courses. By simulating treatment courses we
aim to determine what kind of information on a patient’s past
antibiotic treatments should be considered when assessing the
risk of treatment failure for an upcoming treatment in the future.
We assume that the risk of treatment failure is closely linked
to the prevalence of resistance in the opportunistic pathogen.
This assumption is based on the fact that the probability of the
translocated bacteria containing resistant strains depends on the
frequency of resistance in the opportunistic pathogen population
in the microbiome. The prevalence of resistance is defined in as
the fraction of the opportunistic pathogen population carrying
the resistance plasmid; i.e., P =C+0 /(C
+
0 +C0). To character-
ize the treatment history of the patient over the time span that
the patient was exposed to treatment(s) in the past, we chose
a set of intuitively appealing predictors of the overall treat-
ment regimen provided in Table 1. Predictors such as time to
first treatment after initial colonization (t1 −TI ) and the dura-
tion of the drug-free period after last treatment (Tdf ) capture
the first-order time dynamics of resistance reversal. The num-
ber of treatments (N ) and the total duration of all treatments
(
∑
i di) capture the amount of positive selection applied on the
plasmid-bearing population. Although these predictors reveal
how strongly and for how long the resistance plasmid is posi-
tively selected, they do not contain any information about the
pattern of the treatment history. Therefore, we introduce 2 other
predictors, namely the coefficient of variation (cv ) and the cen-
ter of mass of the treatment pattern (COM ), which represent
the regularity of treatment durations and the time point around
which the treatments are centered, respectively. To illustrate the
choice of these predictors, we present 30 randomly generated
treatment patterns (Fig. 3). This shows that for a fixed amount
of total treatment duration, being treated more intensely toward
the recent past 1) can lead to extinction of the plasmid-bearing
pathogen population since it was not selected strongly enough to
persist in the biome after the initial colonization or 2) can lead
to high prevalence of resistance given that the plasmid persists in
the biome. As a result, center of mass of the treatment pattern
relative to the initial colonization and the regularity of treat-
ment durations become the most intuitive 2 predictors related to
the treatment pattern. In addition to the parameters related to
the treatment regimen, an artificial probe (rnd), which is a ran-
dom variable independent of the response variable (prevalence
of resistance), is also included in the set of predictors. A probe
predictor is a metric used for eliminating all of the other pre-
dictors that are less relevant than it is in assessing the response
variable (53).
Predictor Importance Analysis. To test the relevance of predictors
in assessing the prevalence of resistance, first we use classifica-
tion trees to predict whether the prevalence of resistance within
the pathogen population is positive or zero and second we use
regression trees to predict the numerical value of the preva-
lence of resistance within the pathogen population, given that
it is above zero. Note that the use of classification trees parti-
tions the prevalence of resistance outcome of each simulation
into 2 classes, namely C+0 =0 or C
+
0 > 0, which is important to
understand the influence of the predictors on the extinction of
the resistant pathogen population.
Using an ensemble of these decision trees, we grow random
forests to quantify the importance of each predictor on determin-
ing the prevalence of resistance, which we refer to as predictor
importance analysis. Since our predictors have different scales,
and 2 of them are strongly correlated (number of treatments and
total duration of all treatments), we use unbiased conditional
inference trees (54) and the conditional variable importance
method (55) to calculate the variable importances. Combining
both methods eliminates potential biases due to the scale dif-
ference or the correlation between predictors, but comes at the
cost of increased computational time. Therefore, we analyze only
5, 000 randomly subsampled realizations and 200 trees grown for
both classification and regression forests.
To gain a better understanding of the influence of predictors,
we employ the predictor importance analysis via fixing 1) the
number of treatment courses (N ), 2) the total duration of all
treatments (
∑
i di), and 3) the duration of the drug-free period
after last treatment (Tdf ). Finally, we employ the predictor
importance analysis by randomizing all predictors simultane-
ously for the case of no a priori information on the treatment
history of the patient.
Fixed number of treatment courses. Fig. 4 A and B shows the pre-
dictor importance analysis for each number of treatment courses
varying from 1 to 20. As seen in Fig. 4 A and B, the most
important predictors in general are the duration of drug-free
period after last treatment (Tdf ), total duration of all treatments
(
∑
i di), and the center of mass of the treatment pattern (COM ).
The dependence of their relative importances on the number of
treatment courses can be understood better from Fig. 4C, where
the extinction probability of the resistant pathogen population is
presented given the number of treatment courses (N ) and the
duration of drug-free period after last treatment (Tdf ). Note
that in our model extinction occurs in 2 different ways: Either
the total positive selection applied on the plasmid is not strong
enough for it to persist in the pathogenic population during the
treatment period or the plasmid persists in the population during
the treatment period but becomes extinct during the drug-free
period after the last treatment. When the number of treat-
ments exceeds 8 courses per maximum treatment period allowed
(1,000 d) in our simulations, the resistant pathogen population
increases in abundance to an extent such that the extinction can-
not be observed over a drug-free period of 360 d. Therefore,
the duration of drug-free period after last treatment becomes
unimportant as a predictor of extinction, and the total selection






























































Table 1. List of the predictors used for classification and regression forests with their corresponding descriptions, dependencies,
and range of variations
Predictor Description Dependency Range of variation
rnd The probe predictor. Randomly sampled from a continuous uniform 0–1
distribution on the open interval (0, 1).
Does not depend on other predictors.
N No. of treatment courses within the last 1,000 d. Randomly sampled from the set {1, 2, . . . , 20} 1–20 treatment courses.
treatment courses with equal probability.
Does not depend on other predictors.∑
i di Total duration of all treatments. Represents the Depends on the number of treatment courses 3–200 treatment days.
total drug pressure (in days). and the duration of each treatment course.
dN Duration of the most recent treatment. Randomly sampled from the set {3, 5, 7, 10} d 3–10 treatment days.
with equal probability. Does not depend on
other predictors.
(t1− TI) Time to first treatment after the initial Depends on the total duration of all treatments 1–996 drug-free days.
colonization with the resistant reservoir. due to the maximum 1,000-d constraint on
the treatment period.
Tdf Duration of the drug-free period after the Does not depend on other predictors. 0–360 drug-free days.
most recent treatment.
COM Center of mass of the treatment pattern. Depends on the number, initiation, and 2–998 days
Represents the time point at which the duration of each treatment course.
treatments are centered around relative to
the initial colonization.
cv Coefficient of variation for the duration Depends on the number of treatment courses 0–0.7615†
of treatments. Represents the regularity of and the duration of each treatment course.
treatment durations.
pressure becomes the most important predictor, since it deter-
mines whether extinction occurs within the treatment period or
not (Fig. 4A).
Predictor importances determining the prevalence of resis-
tance (regression results) depend on how close the resistant
pathogenic population is to fixation in the biome. The marginal
effect of additional drug pressure on the abundance of the
resistant population decreases as the plasmid infects a bigger
fraction of the whole population. In this case, resistance preva-
lence depends more on the factors that lead to its decrease (such
as the duration of the drug-free period) rather than its increase
(such as additional drug pressure). This phenomenon is observed
in Fig. 4B, where the center of mass of the treatment pattern
(COM ) and the total duration of all treatments (
∑
i di) are
the most important 2 predictors until the number of treatments
exceeds 9 courses, and the duration of drug-free period (Tdf )
becomes the most important predictor afterward.
Fixed total duration of all treatments. Employing the predictor
importance analysis for different values of total duration of all
treatments (
∑
i di) (Fig. 4 D and E) shows a similar pattern to
the predictor importance analysis for a fixed number of treat-
ment courses (Fig. 4 A and B). Influence of the duration of
drug-free period (Tdf ) and the center of mass of the treatment
pattern (COM ) is prominent in Fig. 4 D and E, similar to Fig. 4
A and B. The same logic on extinction and prevalence of the
resistant pathogenic population applies here as explained in the
previous section on predictor importance analysis for fixed num-
ber of treatment courses. The strong influence of the duration of
the drug-free period (Tdf ) is observed in determining the extinc-
tion up to a total number of 45 treatment days (classification
results). The center of mass of the treatment pattern (COM )
becomes the most important predictor afterward, in agreement
with the extinction probabilities presented in Fig. 4F. The most
important predictor for determining the resistance prevalence
(regression results) switches to the duration of drug-free period
(Tdf ) from the center of mass of the treatment pattern (COM )
between total treatment days of 45 to 50 in Fig. 4E, showing a
similar behavior to that observed in Fig. 4B. Note that the val-
ues at which the most important predictors switch ranking are
dependent on the model parameterization and the selection of
maximum drug-free period (360 d) observed after the last treat-
ment. Qualitatively, these values are dependent on the chance
of extinction during the total treatment period for determining
reversal (classification results) and the chance of fixation dur-
ing the total treatment period for determining the prevalence
(regression results).
Fixed drug-free period after last treatment. The high relative
importance of the duration of drug-free period after the last
treatment Tdf overshadows the influence of other predictors.
Therefore, we employed the predictor importance analysis for
fixed durations of drug-free period varying from 0 to 360 d (Fig. 4
G and H). This analysis shows that when Tdf is kept constant, the
most important 2 predictors are the total duration of all treat-
ments (
∑
i di) and the center of mass of the treatment pattern
(COM ) for determining both the extinction and the prevalence
of resistance.
When all predictors are randomized. Finally, we employ the pre-
dictor importance analysis by randomizing all of the predictors
simultaneously for the case of no a priori information on the
treatment history of the patient. The results presented in Fig. 4I
suggest that the most important 3 predictors in determining the
resistance reversal (classification results) are the duration of the
drug-free period after last treatment (Tdf ), total duration of all
treatments (
∑
i di), and the center of mass of the treatment
pattern (COM ). The most important predictor for determin-
ing the prevalence (regression results) is the drug-free period
after last treatment (Tdf ), emphasizing once again the influence
of first-order time dynamics on resistance spread. Duration of
the most recent treatment (dN ), time to first treatment after the
colonization of the microbiota with resistant commensals (t1 −
TI ), and the regularity of treatment durations (cv ) do not have
an important effect relative to the other predictors.
†Maximum value for cv is obtained in the case of 2 treatment courses, lasting for
3 and 10 d.







































Fig. 3. Illustration of 30 randomly generated treatment patterns, where
the gray pixels represent the time before initial colonization, white pixels
represent the days without treatment after the initial colonization, black
pixels represent the treatment days, and cyan pixels represent the drug-
free time after last treatment. Color bar on the left indicates whether the
resistant pathogenic population has gone extinct or not given the treatment
pattern, and color bar on the right indicates the prevalence of resistance,
sorted in an increasing order from top to bottom. The pink arrow represents
how the center of mass of the treatment pattern moves toward the recent
past of the patient as the prevalence of resistance increases. To isolate the
effects of the treatment pattern only, initial colonization time, drug-free
time after last treatment, total duration of all treatments, and number of
treatments are fixed to 300 d, 60 d, 90 d, and 3 courses, respectively *.
Information Quantification. Knowing the total number of days
that the patient has been exposed to antibiotics (
∑
i di) assumes
that we have complete information on the patient’s medical
history. Unfortunately this detailed information is often not
available in practice, and even if there is information regarding
the past treatments, the likelihood of containing inaccuracies is
substantial (56). Therefore, it is important to quantify how much
one can gain by investigating the patient’s records farther back
in time and understand whether it is necessary to have complete
information to have a good estimate of the prevalence of resis-
tance. To do so, we transformed each realization into a numerical
sequence of days, such that the days before the colonization
with the resistant reservoir, days without treatment, and days
with treatment have zero, negative, and positive impact on the
prevalence of resistance, respectively. Using these sequences, we
applied linear regression to model the impact of each day on the
prevalence of resistance. Detailed information on the methods
used for this analysis is provided in SI Appendix.
*During randomized simulations, the precolonization and the treatment period add up
to 1,000 d, but the lengths of these periods are free to vary.
The magnitude of the linear regression coefficients can be
interpreted as the weights of each day, i.e., the linear contribu-
tion of the activity—being treated or not—at a given day i to the
prevalence of resistance P . As seen in Fig. 5, the largest coeffi-
cients in magnitude belong to the most recent days of the patient
and decay exponentially as one moves farther back in time. This
decay suggests that there is memory in the dynamical system,
and most of the information on the prevalence of resistance is
contained in the most recent treatments of the patient.
Discussion
The development and parameterization of the gut biota model
presented here bring different parts of the literature together
and provide a framework to explore the interaction, con-
jugation, and treatment dynamics in the human gut. More-
over, it describes procedures to assign numerical values to
conjugation- and treatment-related parameters based on empir-
ical data. Using this model, we show that treatment history has a
significant impact on the prevalence of resistance. This impact
can be captured by 3 parameters only. The prevalence of resis-
tance in the opportunistic pathogen population is closely linked
with the risk of treatment failure once an infection occurs. Thus,
our results suggest that future empirical studies on the effect of
previous antibiotic consumption on treatment outcomes might
be the most informative if they focus on those 3 quantities.
More generally, our results allow us to distinguish relevant
from irrelevant characteristics of the treatment history in deter-
mining the prevalence of resistance. First, knowing which factors
determine the prevalence of resistance allows us to better pre-
vent treatment patterns that lead to high risk of treatment fail-
ure. Second, our results suggest what the physician should ask the
patient to assess the risk of treatment failure. Considering that
the duration of the drug-free period after last treatment (Tdf ) is
the most important predictor, the question “When was your last
antibiotic treatment?” becomes a critically important one. Addi-
tionally, the high relative importance of total drug exposure and
the center of mass of the treatment pattern argues that how total
selection pressure is distributed in time is as important as how
much it is applied.
In most cases clinicians will not have complete access to the
patient’s treatment history, and neither will the patients be able
to provide absolutely accurate information on previous antibiotic
use. Therefore, it is important to quantify how much information
one can gain by investigating the patient’s records farther back
in time. As seen in Fig. 5, the relevance of information expo-
nentially decays as one goes farther back in the treatment
history.
Our predictor importance results are consistent with the
reported risk factors on plasmid-mediated resistant infections
cause by enterobacteria in the literature. In ref. 39, total prior
antibiotic use was found to be the only independent risk factor
for ESBL-producing E. coli and K. pneumoniae infections, which
confirms the importance of the predictor total duration of all
treatments (
∑
i di). In refs. 38, 40, and 41, the authors report that
the recent use of antibiotics is found to be an independent risk
factor for a resistant infection with plasmid-bearing enterobacte-
ria. These findings support our results on the importance of the
duration of drug-free period after last treatment (Tdf ), as well as
the analysis provided in Fig. 5. The agreement of our results with
the clinical studies confirms that quantifying the prevalence of
resistance for a particular patient with a particular treatment his-
tory may help clinicians to make more personalized and precise
decisions on the choice of future treatments, rather than relying
on the statistical information calculated over regions, sexes, or
age groups.
This study has several limitations and strengths. First, the
parameterization of our model is based on the current state































































































Fig. 4. Predictor importance analysis and extinction probabilities of the resistant opportunistic pathogen population. Conditional predictor importance
values are calculated over 5,000 samples and 200 trees and normalized between 0 and 1. Extinction probabilities are calculated using 600,000 randomly
subsampled realizations, 1,200 realizations per N = {1, 2, . . . , 20} per Tdf = {0, 15, 30, . . . , 360} value. (A and B) Normalized conditional predictor impor-
tance values for (A) classification and (B) regression, for different values of number of treatment courses (N) varying from 1 to 20. (C) Extinction probability
of the resistant pathogen population given the number of treatment courses (N) and the duration of drug-free period after last treatment (Tdf ). (D and E)
Normalized conditional predictor importance values for (D) classification and (E) regression, for different values of total duration of all treatments (
∑
i di)
varying from 3 to 150 d. (F) Extinction probability of the resistant pathogen population given the total duration of all treatments (
∑
i di) and the duration
of drug-free period after last treatment (Tdf ). (G and H) Normalized conditional predictor importance values for (G) classification and (H) regression, for
different values of the duration of drug-free period after last treatment (Tdf ) varying from 0 to 360 d. (I) Normalized conditional predictor importance
values for classification and regression when all predictors are randomized.
of the literature, which contains substantial knowledge gaps.
Samples used for estimating interaction and growth parameters
in ref. 11 were in OTU reads of 2 healthy subjects, but the
biomass of the collected samples was not reported. Therefore,
we assumed that the total biomass in the subjects’ unperturbed
biota is to a good approximation constant, allowing us to esti-
mate the parameters for our absolute abundance-based model
from frequency-based OTU reads. When the microbiota are sub-
jected to antibiotics, we assume that the same parameter values
hold although the total biomass of the microbiota shrinks in our
model. In other words, we assume that the parameters are not
density dependent.
It is known that resistance persists in the human gut for a
certain amount of time in the absence of antibiotics, but there
is not enough evidence to assess the time required to lose
plasmid-mediated resistance or to fully understand which prop-
erties of the human biome influence this quantification. More
importantly, studies on the effects of antibiotics on the human
gut microbiota—including the ones referred to in this work—
provide conclusions that are more qualitative than quantitative.
In vitro time-kill assays provide sufficient data for certain antibi-
otics applied to certain strains of bacteria, but how these data
translate to the in vivo dynamics of the human gut is cur-
rently not known. The absence of such information enforces
the parameterization of the treatment dynamics to be done
via relevant metadata, instead of estimating the corresponding
parameters directly.
Second, our model makes several important simplifications.
We model the gut biota as it is a closed system, with no immigra-
tion or emigration of bacteria. This assumption does not permit
the recolonization of the gut microbiome with a plasmid-bearing
population, which might contribute to the prevalence of resis-
tance in a similar fashion to that of an additional treatment
course. On the other hand, it permits us to isolate the effects
of treatment on the prevalence of resistance only. Although
gut biota is not a closed system in reality, we believe that the
main conclusions of the model would still be valid as long as
the relative abundances of phyla or the absolute abundance of
plasmid-bearing bacteria do not alter drastically. By modeling
the gut microbiome on a phylum level, we neglect the growth,







































Fig. 5. Absolute values of the linear regression coefficients given the day
index i, calculated using 600,000 randomly subsampled realizations, 1,200
realizations per N = {1, 2, . . . , 20} per Tdf = {0, 15, 30, . . . , 360} value. The
red curve represents the exponential decay function in the form of a× e−bi ,
fitted to the magnitude of the linear regression coefficients to demonstrate
the exponential decay of contribution of information as one moves farther
back in the treatment history of the patient.
interaction, and conjugation dynamics within each phylum. We
further assume that plasmid-bearing variants of Proteobacteria
and Bacteroidetes interact with other phyla in the same man-
ner as their sensitive counterparts. Both assumptions permit the
model to have low complexity, but they force us to merge param-
eters related to many different species of the same phylum into
one. Finally, we do not consider the emergence of resistance in
vivo in the presence of drug pressure. Given that the gut biome
already contains a plasmid-bearing resistant population prior to
the treatments, we anticipate that the in vivo emergence of chro-
mosomal resistance and its vertical transfer will have a negligible
effect compared to the horizontal spread of resistance that is
already present.
Given the level of randomization in the simulated treatment
courses and the number of dynamical variables that our model
outcome (prevalence of resistance) depends on, we focused on
simulations only and leave potential analytical approaches for
future work.
A key strength of this work is that it simultaneously cap-
tures the dynamics of antibiotic resistance in pathogenic bac-
teria and the microbiome as well as the plasmid-mediated
exchange between these populations. It integrates a wealth of
in vitro and in vivo measurements on the key drivers of resis-
tance and on the ecological dynamics of the microbiome. Thus,
even though there are several important knowledge gaps and
simplifications, the presented model represents in our view
a very feasible approach incorporating the currently available
knowledge of the evolution of resistance in the microbiome.
Finally, applying this framework to the question of the impact
of previous antibiotic consumption at the level of an individ-
ual patient helps to elucidate how complex patterns of antibi-
otic consumption may drive the prevalence of resistance in
an individual.
Materials and Methods
Gut Microbiota Model. The first step toward building this model is to choose
the appropriate level of representation for the human gut microbiota. The
gut microbial composition shows substantial interindividual variation, as
well as intraindividual temporal fluctuations on a species level. On the level
of bacterial phyla, however, the community composition exhibits temporal
stability within an individual (57–60). This temporal stability is relevant for
the modeling as it allows us to parameterize the model using steady-state
solutions. Moreover, using a phylum-level description decreases the number
of equations and parameters of the model, thus making parameteriza-
tion more constrained. Therefore, our model incorporates only the 4 most
abundant phyla in the human gut microbiome, which are Proteobacteria,
Bacteroidetes, Firmicutes, and Actinobacteria.
We assume that the community harbors a conjugative PMQR plasmid
which spreads only among gram-negative bacteria, i.e., Proteobacteria and
Bacteroidetes. These 2 assumptions reflect the following observations: 1)
PMQR genes have been found in a variety of Enterobacteriaceae, especially
E. coli and species belonging to the genera Enterobacter, Klebsiella, and
Salmonella (61–65), as well as enteric Bacteroidetes species (66); 2) PMQR
genes are usually found on conjugative plasmids (61, 63, 67, 68); and 3)
although these genes are found in a variety of gram-positive organisms,
they are chromosomal but not plasmid mediated (69, 70). As we are inter-
ested in the effect of treatment history on plasmid-mediated resistance, we
ignore de novo emergence of resistance. Plasmid-free cells acquire the plas-
mid only via conjugation, and plasmid-bearing cells might lose the plasmid
due to segregation. Bearing the plasmid imposes a fitness cost on the host
by reducing the growth rate. We assume that only plasmid-free, i.e., sen-
sitive bacteria are affected by treatment, based on the evidence that the
presence of PMQR genes significantly reduces the therapeutic efficacy of CIP
in vivo (71–74).
Among gram-negative bacteria, Bacteroidetes play an important role
in the in vivo transfer of resistance genes (47, 75, 76) and can serve as
a reservoir of resistance determinants to pass onto more virulent bacte-
ria (77–79). Also considering their high abundance in the human colon
(80), the resistance reservoir function of the gut microbiota is attributed
to the Bacteroidetes phylum in our model. Given that many common
human pathogens are found in the Proteobacteria phylum (81), we assume
that the opportunistic pathogens in our model are members of Pro-
teobacteria. Since we are interested in modeling a single individual, the
gut microbiome is assumed to be a closed system with no influx or
efflux of bacteria.
Based on the assumptions above, we build a mathematical model which
incorporates growth, interaction, conjugation, and the treatment dynam-
ics, given by Eqs. 1 and 2. Each phylum is denoted by the index i, where C0,
C1, C2, and C3 represent the phyla Proteobacteria, Bacteroidetes, Firmicutes,
and Actinobacteria, respectively. Plasmid-bearing variants of Proteobacteria
and Bacteroidetes are denoted by C+0 and C
+
1 and assumed to interact with
other phyla in the same manner as their sensitive counterparts. Conjuga-
tion occurs via mass action kinetics at a rate proportional to the densities of
plasmid-bearing and plasmid-free bacteria (14, 16, 82). The term µi denotes
the net growth rate of phylum i in the absence of any interaction, and
the interaction terms aij denote the effect of phylum j on phylum i. The
cost imposed on phylum i due to plasmid carriage is denoted by ρi and
reduces the growth rate of phylum i by a factor of (1− ρi). The terms hij
stand for the conjugation frequency between phylum j and phylum i, and
γ denotes the fraction of plasmid-free cells after plasmid-bearing cell segre-
gation, i.e., the missegregation fraction. A time-dependent binary indicator
is included in the system to indicate whether a treatment is being applied or
not, denoted by 1T , and is equal to 0 (1) in the absence (presence) of treat-
ment. During treatment, 1T becomes 1 and activates the death rate term
δi of phylum i due to drug exposure. Since we assume that conjugation
occurs only among gram-negative bacteria, C+2 (t) = 0 and C
+



































Growth and interaction parameters. After constructing the dynamical sys-
tem, we proceed with estimating the numerical values of the system
parameters. To our knowledge no in vivo study exists that longitudi-
nally monitors composition of phyla and resistance-conferring plasmids in
presence and absence of antibiotics. Therefore we obtain numerical val-
ues for the growth and interaction parameters by fitting to longitudinal






























































Table 2. Model parameters given with their descriptions, sampling ranges, sampling schemes,
and constraints
Parameter Description Range Sampling Constraint
ρ0 Resistance cost for C
+
0 [0.01, 0.2] Linear ρ1 <ρ0
ρ1 Resistance cost for C
+
1 [0.01, 0.2] Linear ρ1 <ρ0
hintra Intraphyla conjugation frequency [10−18, 10−14] Logarithmic hintra >hinter
hinter Interphyla conjugation frequency [10−18, 10−14] Logarithmic hintra >hinter
γ Missegregation fraction [0.01, 0.05] Linear
abundance data of bacterial phyla and obtain parameters for conjugation
and treatment from other sources.
To estimate the terms µi and aij , we utilize the phylum-level time
series data obtained from 2 healthy subjects’ gut microbiota (referred
as F4 GUT and M3 GUT) provided in ref. 11. Samples presented in ref.
11 were in OTU reads, with an average sampling interval of 1.12 d. To
infer parameters invariant to the scale of the data, we normalized the
OTU reads across all phyla for each time point and used the resulting
quotients for Proteobacteria, Bacteroidetes, Firmicutes, and Actinobacteria
as a proxy for their abundance in the gut. The Bayesian variable selec-
tion algorithm in MDSINE (83) is adopted for the time series analysis
of the data.
Conjugation frequencies, resistance costs, and missegregation fraction.
Persistence of a plasmid is largely driven by the relative magnitude of
its fitness cost and missegregation fraction compared to its conjugation
efficiency (84). Therefore, the decay rate of plasmid-bearing bacteria in
a mixed population is determined by the numerical combination of fit-
ness costs (ρi), conjugation frequencies (hij), and missegregation fraction
(γ). Merging these 3 parameters into 1, i.e., the decay rate, gives us
the opportunity to obtain numerical values for ρi , hij , and γ jointly by
imposing proper constraints on the temporal stability of the plasmid
in our model.
In the absence of antibiotics, as long as the resistance plasmid imposes
a fitness cost, plasmid-bearing cells are replaced by their plasmid-free
counterparts over a sufficiently long time, effectively reversing resistance
(84–90). It has been hypothesized that plasmid-mediated resistance rever-
sal is more likely to happen in in vivo compared to in vitro experiments
(91), although it might take longer periods than previously anticipated due
to certain adaptation mechanisms. It has been shown that PMQR plasmids
were able to persist in the digestive tract of chickens for several weeks
(87), and multidrug resistance plasmids persisted in human infant gut micro-
biota for several months (92). In vivo studies with mice also demonstrated
the long-term persistence of plasmid-encoded resistance in the absence
of treatment (93) and showed that it is possible to observe the resis-
tant determinants up to 4 y after the drug pressure is removed (94, 95).
Furthermore, frequency of a conjugative plasmid that confirms resistance
against sulphonamide remained high for 8 y in the United Kingdom despite
the national prescribing restriction (96). Additional information specific to
human gut suggests that resistant strains—although not necessarily plasmid
mediated—persisted for 1 to 3 y after the termination of the treatment (79,
97–99). Considering all of the evidence in the literature, we choose an inter-
mediate value and assume that the PMQR plasmid in our model persists in
the gut microbiome for 2 y in the absence of treatment.
Persistence of a plasmid can be associated with different stabilization
mechanisms, such as increasing the copy number of the plasmid, active parti-
tioning, and postsegregational killing (88, 100, 101). Among these, reducing
the cost of plasmid carriage is the most crucial one, since the main fac-
tor determining whether resistant populations can be replaced by their
sensitive counterparts is the biological fitness cost of resistance (100). Ame-
lioration of the cost of plasmid carriage and thereby facilitating plasmid
stability via compensatory evolution have been demonstrated by a number
of in vitro studies (102–105). Therefore, to distinguish the reservoir function
of Bacteroidetes, we assume that they acquired compensatory mutations to
lower the cost of plasmid carriage, whereas the pathogenic population Pro-
teobacteria bears a larger cost. This is expressed in the model by imposing
the constraint ρ1 <ρ0.
Conjugative plasmids are highly promiscuous: Donor and recipient cells
may belong to different genera or even to different kingdoms (106, 107).
Despite their promiscuity, successful conjugation between highly divergent
species is expected to occur at significantly reduced frequencies due to bot-
tlenecks in conjugative transfer (108–110). Thus, we assume that intraphyla
conjugation occurs at a higher frequency than interphyla conjugation. For
the sake of simplicity, we assign a single quantity for the intraphylum and
interphyla conjugation frequency for both Bacteroidetes and Proteobac-
teria, such that hintra = h00 = h11 and hinter = h10 = h01, and impose the
constraint hintra > hinter.
Taking all constraints, we employ a random sampling scheme to jointly
assign numerical values for hintra, hinter, ρ0, ρ1 and γ such that the total
plasmid-bearing population (C+0 + C
+
1 ) goes extinct after 2 y in the absence
of treatment. We assume that the patient is initially colonized with PMQR-
plasmid–bearing Bacteroidetes of inoculum size 106 colony-forming units
(cfu) (111); i.e., C+1 (0) = 10
6 cfu, given that the total abundance of bacteria
in the human gut is ≈O(13) cfu (112). These values lead to a proportion
of C+1 (0)/(C
+
1 (0) + C1(0)) = 1.6× 10
−7 at the initial time of colonization.
C+0 (0) is set to 0 to observe the effects of the reservoir alone. Sam-
pling ranges for the parameters are given in Table 2, with corresponding
sampling schemes and constraints imposed on each parameter. To account
for the stochasticity in our simulations, we run 1,000 realizations for a
given {hintra, hinter, ρ0, ρ1, γ} set and calculate the mode of the extinc-
tion time distribution for each set. Out of 10,000 randomly sampled sets,
we observed only 1 set with a mode of 720 d for plasmid extinction, and
this set is used for simulating the treatment courses. Note that more sets
can be observed with a larger sampling size with the cost of a longer
computational time.
Death rates due to drug exposure. To assign numerical values to death rates
of the sensitive bacteria in the presence of treatment, we refer to studies
which investigate the effects of short-term antibiotic treatment on the
human gut microbiota. These studies provide both qualitative and quan-
titative information that can be used to determine the values for death
rates. Given the data presented in refs. 49–52 for human subjects and in
Table 3. Summary of the literature on gut microbiota response after short-term antibiotic treatment
Study Exclusion criteria Treatment Observations
(49) Antibiotic use within previous 10 d × 1 course 500 mg CIP Decreased relative abundance of Firmicutes,
2 mo or hospitalization twice, daily increased relative abundance of Bacteroidetes,
within previous 30 d. recovery in 4 wk.
(50) Significant medical 3 d × 1 course 500 mg CIP Overall diversity of the gut microbiota was
problems. twice, daily largely restored 28 d after treatment.
(51) Antibiotic use within 5 d × 1 course 500 mg CIP Community composition 4 wk after treatment is
previous 12 mo. twice, daily within the range of temporal variability of pretreatment.
(52) Antibiotic use within 6 d × 1 course 500 mg CIP Decreased relative abundance of Proteobacteria.
previous 12 mo. twice, daily Diversity recovered almost fully 28 d after treatment.
(113) − 3 d of vancomycin and 10-fold decrease in bacterial load right
imipenem intake after treatment.







































Fig. 6. Random sampling scheme employed for assigning numerical values for death rates δ0, δ1, δ2, δ3.
ref. 113 for rats, we assume that 1) relative abundances of phyla recover
approximately 28 d after CIP treatment, 2) relative abundance of Bac-
teroidetes increases in response to CIP treatment, 3) relative abundance
of Firmicutes decreases in response to CIP treatment, 4) relative abun-
dance of Proteobacteria decreases in response to CIP treatment, and 5)
total bacterial load decreases 10-fold in response to 3-d antibiotic treat-
ment. A summary of the literature on the effects of short-term antibiotic
treatment on the gut microbiota is presented in Table 3. Using the infor-
mation provided in these studies, we use a random sampling scheme
to jointly assign numerical values for δi for i = {0, 1, 2, 3}, which is pre-
sented as a diagram in Fig. 6 to further clarify the process. Since resis-
tance is not considered in the studies mentioned above, we assumed a
fully sensitive population without any chromosomal or plasmid-mediated
resistance.
Simulated Treatment Courses. To quantify the impact of past treatments
on the composition of the gut microbiota, we simulate the parameter-
ized model employing treatment courses that include randomly initiated
treatments with randomly chosen durations, which we refer as “random
treatment.” We use a hybrid stochastic–deterministic simulation method
adapted from ref. 48 to simulate the system of equations given by Eqs. 1 and
2. This method approximates the fast reactions associated with species with
high abundance as continuous processes, whereas all other reactions are
realized as discrete stochastic processes, thus decreasing the computational
cost.
As mentioned in Gut Microbiota Model, we assume that the patient is
colonized with PMQR-plasmid–bearing Bacteroidetes prior to the initiation
of treatment(s). Time of initial colonization is denoted by the random vari-
able TI and assumed to occur at most 1,000 d before the termination of
the last treatment. The last day of exposure to drugs, i.e., the last day of
the last treatment, is denoted by TL, and the patient receives a number of
N treatments between TI and TL, where N is uniformly distributed in the
set {1, 2, . . . , 20}. We chose to use a uniform distribution on the number
of treatment courses (N) to cover a broad range of treatment frequencies
and do not make any a priori assumptions on the treatment frequency.
If empirical information on the distribution of the number of treatment
courses (N) is available, one could consider a more realistic distribution on
N (Poisson, normal, etc.) which might lead to better quantitative predic-
tions of the resistance prevalence. Initiation time and the duration of the
ith treatment are denoted by ti and di , respectively, where di is uniformly
distributed in the set {3, 5, 7, 10} d. After N is chosen, ti and di are sampled
together for every ith treatment in a sequential way, by putting at least
1 drug-free day between 2 consecutive courses of treatment. As a result,
(TL− TI) =
∑N
i ti + di + 1≤ 1,000 is satisfied for each realization. Samples
related to the gut microbiome content of the patient are collected Tdf days
after TL, where Tdf denotes the drug-free days after the termination of the
last treatment and varies in the set {0, 15, 30, . . . , 360} d. The timeline used
in the simulations is demonstrated in Fig. 7.
As mentioned in Predictor Importance Analysis, using the methods in
refs. 54 and 55 in combination corrects for the scale differences among
the predictors. Therefore, the relative importance of a predictor is robust
to its range of variation as long as this variation is high enough to
induce a change in the response variable (prevalence of resistance). If
the given range of values does not permit the predictor to affect the
Fig. 7. Timeline used for the simulated treatment courses, where TI, TL, and Tdf denote the initial colonization with the plasmid-bearing commensals, the
last day of drug exposure, and drug-free days after the end of the last treatment, respectively. Initial colonization is assumed to occur at most 1,000 d before
the termination of the last treatment, and therefore TL− 1,000≤ TI ≤ TL. Every ith treatment starts at ti and lasts for di days.






























































response variable, the predictor becomes practically irrelevant. This can
be observed in Fig. 4A where the relative importance of Tdf goes down
to 0 after the number of treatment courses exceeds 9, simply because no
extinction is observed during the drug-free period when the number of
treatment courses is 10 or higher (Fig. 4C). Therefore, when applying pre-
dictor importance analysis, the best practice is to keep the variation of
the independent predictors as high as possible to allow for changes in the
response variable.
Source code for this project is available at https://github.com/
burcutepekule/gutmicrobiota.
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